Predilife Asset Resilience Ratio
Predilife asset resilience ratio. Predilife (ALPRE) has an Asset Resilience Ratio of 16.23% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALPRE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Predilife (2016–2024)
Asset resilience ratio of Predilife from 2016 to 2024. This chart shows how Predilife's Asset Resilience Ratio has changed over time. Read debt load of Predilife for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Predilife's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ALPRE total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €212.11K | 16.23% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €212.11K | 16.23% |
Asset Resilience Insights
- Good Liquidity Position: Predilife maintains a healthy 16.23% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Predilife Industry Peers by Asset Resilience Ratio
Compare Predilife's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 13.87% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Microba Life Sciences Ltd
AU:MAP |
Diagnostics & Research | 11.53% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Predilife Asset Resilience Ratio by Year (2016–2024)
Predilife asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Predilife.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.69% | €701.00K ≈ $819.54K |
€2.44 Million ≈ $2.86 Million |
+7.86pp |
| 2023-12-31 | 20.82% | €1.84 Million ≈ $2.15 Million |
€8.82 Million ≈ $10.31 Million |
+16.85pp |
| 2022-12-31 | 3.98% | €188.86K ≈ $220.80K |
€4.75 Million ≈ $5.55 Million |
-0.81pp |
| 2021-12-31 | 4.79% | €189.80K ≈ $221.89K |
€3.97 Million ≈ $4.64 Million |
+0.58pp |
| 2020-12-31 | 4.21% | €172.54K ≈ $201.71K |
€4.10 Million ≈ $4.79 Million |
-8.51pp |
| 2019-12-31 | 12.72% | €171.72K ≈ $200.76K |
€1.35 Million ≈ $1.58 Million |
+8.73pp |
| 2018-12-31 | 3.99% | €92.00K ≈ $107.56K |
€2.31 Million ≈ $2.70 Million |
-18.29pp |
| 2016-12-31 | 22.28% | €551.66K ≈ $644.95K |
€2.48 Million ≈ $2.89 Million |
-- |
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer pred… Read more